JP2004529931A5 - - Google Patents

Download PDF

Info

Publication number
JP2004529931A5
JP2004529931A5 JP2002583031A JP2002583031A JP2004529931A5 JP 2004529931 A5 JP2004529931 A5 JP 2004529931A5 JP 2002583031 A JP2002583031 A JP 2002583031A JP 2002583031 A JP2002583031 A JP 2002583031A JP 2004529931 A5 JP2004529931 A5 JP 2004529931A5
Authority
JP
Japan
Prior art keywords
methyl
trifluoromethyl
bis
tolyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002583031A
Other languages
English (en)
Japanese (ja)
Other versions
JP4146730B2 (ja
JP2004529931A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2002/001085 external-priority patent/WO2002085458A2/en
Publication of JP2004529931A publication Critical patent/JP2004529931A/ja
Publication of JP2004529931A5 publication Critical patent/JP2004529931A5/ja
Application granted granted Critical
Publication of JP4146730B2 publication Critical patent/JP4146730B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2002583031A 2001-04-23 2002-02-02 良性前立腺肥大に対するnk−1受容体拮抗薬の使用 Expired - Lifetime JP4146730B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01109853 2001-04-23
PCT/EP2002/001085 WO2002085458A2 (en) 2001-04-23 2002-02-02 Use of nk-1 receptor antagonists against benign prostatic hyperplasia

Publications (3)

Publication Number Publication Date
JP2004529931A JP2004529931A (ja) 2004-09-30
JP2004529931A5 true JP2004529931A5 (enExample) 2005-08-04
JP4146730B2 JP4146730B2 (ja) 2008-09-10

Family

ID=8177209

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002583031A Expired - Lifetime JP4146730B2 (ja) 2001-04-23 2002-02-02 良性前立腺肥大に対するnk−1受容体拮抗薬の使用

Country Status (17)

Country Link
US (1) US20030004157A1 (enExample)
EP (1) EP1385577B1 (enExample)
JP (1) JP4146730B2 (enExample)
KR (1) KR100599134B1 (enExample)
CN (1) CN100398106C (enExample)
AR (1) AR035935A1 (enExample)
AT (1) ATE323531T1 (enExample)
AU (1) AU2002250876B2 (enExample)
BR (1) BR0209151A (enExample)
CA (1) CA2444395C (enExample)
DE (1) DE60210760T2 (enExample)
DK (1) DK1385577T3 (enExample)
ES (1) ES2261657T3 (enExample)
MX (1) MXPA03009720A (enExample)
PT (1) PT1385577E (enExample)
WO (1) WO2002085458A2 (enExample)
ZA (1) ZA200308110B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002259147A1 (en) * 2001-05-08 2002-11-18 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
US6849624B2 (en) 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
CN100562320C (zh) 2003-01-31 2009-11-25 弗·哈夫曼-拉罗切有限公司 2-(3,5-二-三氟甲基-苯基)-N-[6-(1,1-二氧代-1λ6-硫代吗啉-4-基)-4-(4-氟-2-甲基-苯基)-吡啶-3-基]-N-甲基-异丁酰胺的新晶体变体
JP4490421B2 (ja) * 2003-07-03 2010-06-23 エフ.ホフマン−ラ ロシュ アーゲー 統合失調症を処置するデュアルnk1/nk3アンタゴニスト
ES2246687B2 (es) * 2004-02-11 2006-11-16 Miguel Muñoz Saez Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
EP1776342B1 (en) 2004-07-06 2011-03-02 F. Hoffmann-La Roche AG Process for preparing carboxamide pyridine derivatives used as intermediates in the synthesis of nk-1 receptor antagonists
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
CN101128189A (zh) 2005-02-25 2008-02-20 弗·哈夫曼-拉罗切有限公司 药物物质分散性改善的片剂
ES2778846T3 (es) 2005-11-08 2020-08-12 Vertex Pharma Moduladores heterocíclicos de transportadores de casete de unión a ATP
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
JP2010516734A (ja) 2007-01-24 2010-05-20 グラクソ グループ リミテッド 3,5−ジアミノ−6−(2,3−ジクロロフェニル)−1,2,4−トリアジンまたはr(−)−2,4−ジアミノ−5−(2,3−ジクロロフェニル)−6−フルオロメチルピリミジンを含む医薬組成物
CN102863432B (zh) 2007-05-09 2016-09-07 沃泰克斯药物股份有限公司 Cftr调节剂
WO2009076142A2 (en) 2007-12-07 2009-06-18 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxiamido-pyridine benzoic acids
KR20150063170A (ko) 2007-12-07 2015-06-08 버텍스 파마슈티칼스 인코포레이티드 3-(6-(1-(2,2-디플루오로벤조[d][1,3]디옥솔-5-일)사이클로프로판카복스아미도)-3-메틸피리딘-2-일)벤조산의 고체 형태
CN106432213A (zh) 2008-02-28 2017-02-22 沃泰克斯药物股份有限公司 作为cftr调节剂的杂芳基衍生物
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
MX2011009700A (es) 2009-03-17 2011-12-08 Daiichi Sankyo Co Ltd Derivado de amida.
WO2010119347A1 (en) * 2009-04-14 2010-10-21 Helsinn Healthcare S.A. Netupitant for use in treating bladder dysfunction
US20120196901A1 (en) * 2009-10-29 2012-08-02 Merck Sharp & Dohme Corp. Tertiary amide orexin receptor antagonists
BR112012026255A2 (pt) 2010-04-07 2017-03-14 Vertex Pharma composições farmacêuticas de ácido 3-(6-(1-(2-,2-difluorbenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzóico e administração das mesmas
DK2806859T3 (da) 2012-01-25 2019-08-05 Vertex Pharma Formuleringer af 3-(6-(1-(2.2-difluorbenzo[d][1,3]dioxol-5-yl) cyclopropancarboxamido)-3-methylpyridin-2-yl)benzoesyre
CA2930008A1 (en) 2013-11-08 2015-05-14 Kissei Pharmaceutical Co., Ltd. Carboxymethyl piperidine derivative
DK3068392T5 (da) 2013-11-12 2021-09-20 Vertex Pharma Fremgangsmåde til fremstilling af farmaceutiske sammensætninger til behandlingen af cftr-medierede sygdomme
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
WO2016081556A1 (en) 2014-11-18 2016-05-26 Vertex Pharmaceuticals Incorporated Process of conducting high throughput testing high performance liquid chromatography
EP3746077A4 (en) * 2018-02-02 2021-10-27 Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) PARENTERAL FORMULATIONS AND USES THEREOF

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6175013B1 (en) * 1994-06-10 2001-01-16 Eli Lilly And Company Imidazolinyl tachykinin receptor antagonists
FR2729951B1 (fr) * 1995-01-30 1997-04-18 Sanofi Sa Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant
PL338453A1 (en) * 1997-08-06 2000-11-06 Lilly Co Eli 2-acylaminopropanoamines as antagonists of the tachykinin receptor
JP2001512717A (ja) * 1997-08-06 2001-08-28 イーライ・リリー・アンド・カンパニー タキキニン受容体アンタゴニストとしての2−アシルアミノプロパンアミン
JPH11322748A (ja) * 1998-03-19 1999-11-24 Takeda Chem Ind Ltd 複素環化合物、その製造法および用途
DE60045564D1 (de) * 1999-02-24 2011-03-03 Hoffmann La Roche 4-Phenylpyridinderivate und deren Verwendung als NK-1 Rezeptorantagonisten
WO2000067742A2 (en) * 1999-05-05 2000-11-16 Warner-Lambert Company Use of gaba analogues for the modulation of substance p
CA2415890C (en) * 2000-07-14 2009-04-07 F. Hoffmann-La Roche Ag N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides

Similar Documents

Publication Publication Date Title
JP2004529931A5 (enExample)
CA2444395A1 (en) Use of nk-1 receptor antagonists against benign prostatic hyperplasia
CA2299139A1 (en) 4-phenyl-pyridine derivatives
JP2004504301A5 (enExample)
RU2010110640A (ru) Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ
RU2003102612A (ru) N-окиси в качестве пролекарств производных 4-фенилпиридина, являющихся натагонистами рецептора nk-1
JP2010538076A5 (enExample)
RU2425838C2 (ru) Ингибиторы iap
RU2458920C2 (ru) Новые соединения
JP2007519754A5 (enExample)
JP2004532227A5 (enExample)
CA2663366A1 (en) Compounds and compositions as protein kinase inhibitors
HRP20161011T1 (hr) Aril dihidropiridinoni i piperidinoni kao inhibitori mgat2
JP2004504400A5 (enExample)
FI3743406T3 (fi) Tmem16a-modulaattoreita
NZ588652A (en) Carboxamide compounds for the treatment of metabolic disorders
RU2009116670A (ru) Производные 3-пиридинкарбоксамида и 2-пиразинкарбоксамида в качестве агентов, повышающих уровень лвп-холестерина
JP2016506964A5 (ja) ナトリウムチャネルの調節剤としてのキノリンおよびキノキサリンアミド
JP2015517981A5 (enExample)
CA2416874A1 (en) 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists
JP2010530438A5 (enExample)
NZ591427A (en) P38 map kinase inhibitors
JP2006511474A5 (enExample)
RU2012152639A (ru) Пиколинамидные и пиримидин-4-карбоксамидные соединения, способ их получения и фармацевтическая композиция, включающая их
CA2648569A1 (en) Pyridyl amide t-type calcium channel antagonists